Scientific deep-dive
Which Exercise Reduces Visceral Fat Most? What Network Meta-Analyses Show
HIIT tops two 2026 network analyses on visceral fat, but combined or aerobic training leads in other groups, and head-to-head trials are less convincing. Resistance training ranks last each time. Here are the rankings, doses and caveats.
No exercise type has a settled win on visceral fat, though resistance training alone ranks last with striking consistency. High-intensity interval training (HIIT) ranked first in two 2026 network meta-analyses of people with overweight or obesity, including one of 61 randomized trials with no age limit (standardized mean difference, or SMD, -0.84 against no exercise; 95% CI -1.08 to -0.61)[1][2]. Combined training ranked first in people with prediabetes or type 2 diabetes[4], aerobic training ranked first in people with early cardiometabolic disease[5], and an analysis of direct head-to-head trials found HIIT no better than continuous cardio[7].
The rankings side by side
A network meta-analysis combines direct and indirect comparisons so that treatments never tested against each other can still be ranked. The five analyses below come from Chang 2026[1], Xu 2026[2], Chen 2024[3], Khalafi 2026[4] and Wei 2026[5]. They search much of the same literature, so they should not be read as five independent confirmations.
| Analysis | Trials and people | Population | Ranking, best to last | Reported effects |
|---|---|---|---|---|
| Chang 2026 | 61 RCTs; 4,136 | Overweight or obesity, no comorbid conditions, no age limit | HIIT, combined, aerobic, resistance | HIIT -0.84; combined -0.54; aerobic -0.53; resistance -0.41 |
| Xu 2026 | 60 RCTs; 3,308 | Adults with overweight or obesity | HIIT, combined, aerobic, resistance | HIIT -0.74; rank scores 72.5%, 69.1%, 59.0%, 49.5% |
| Chen 2024 | 84 RCTs; 4,836 | Overweight or obesity | Vigorous aerobic and HIIT highest; resistance least effective | No effect sizes in the abstract |
| Khalafi 2026 | 33 trials; 1,740 | Prediabetes or type 2 diabetes | Combined, HIIT, aerobic, resistance | Combined -0.63; HIIT -0.53; aerobic -0.38; resistance -0.25 (not significant) |
| Wei 2026 | 37 RCTs; 3,483 (20 studies, 1,464 people for visceral fat) | Stage 1 cardiovascular-kidney-metabolic syndrome | Aerobic, HIIT, combined, resistance | Aerobic -0.44; HIIT -0.32; combined -0.31; resistance -0.27 (not significant) |
Two terms need translating. An SMD expresses change in standard deviation units, used here because trials measured visceral fat in different ways, so it can’t be converted into square centimeters or inches. Rank scores (SUCRA or P-score) describe the probability of a treatment placing high, which is not the same as how much better it is.
How firm is HIIT’s first place?
Less firm than a first-place ranking implies. The two 2026 analyses of overweight and obesity gave the same order but very different confidence: a HIIT rank score of 99.3% in one[1] and 72.5% in the other, where combined training sat just behind at 69.1%[2]. The second team wrote that differences between active exercise types were relatively small and that confidence intervals for those comparisons overlapped[2].
The first team reported HIIT as significantly better than aerobic exercise (SMD 0.31), resistance training (0.43, 95% CI 0.13 to 0.73) and combined training (0.31, 95% CI 0.01 to 0.60), but rated the certainty of those comparisons low, very low and moderate respectively[1]. Their own limitations section notes that visceral fat was assessed by DXA, MRI, CT, ultrasound, bioimpedance devices and formula-derived indices, and that diet, energy deficit and adherence were inconsistently reported[1]. The second team downgraded its ranking evidence for suspected publication bias[2].
Direct comparisons are more sobering. A meta-analysis of 11 randomized trials using DXA found no visceral advantage for HIIT over continuous aerobic training (SMD -0.05, 95% CI -0.29 to 0.19)[7]. A larger review of low-volume interval work, 56 studies and 1,831 people, did find low-volume HIIT better than moderate continuous training (SMD -0.53), though not sprint interval training, and its authors rated the certainty of evidence as low[8]. Our HIIT review reaches a similar conclusion for total body fat, along with the real caveats about training hard during GLP-1 dose increases.
Population changes the winner
Results shift when the people studied shift. In prediabetes and type 2 diabetes, combined training had the highest rank (P-score 0.89), followed by HIIT (0.76), aerobic training (0.52) and resistance training (0.32)[4]. In adults with stage 1 cardiovascular-kidney-metabolic syndrome, aerobic training led, and length seemed to matter: HIIT ranked first in programs of 12 weeks or less (rank score 67%), aerobic training in longer ones (94.9%)[5]. That review rated certainty for visceral fat generally low to very low[5].
People with a BMI at or below 27 are less studied. A review of 13 studies and 354 participants found a large pooled effect in controlled comparisons (SMD -1.590, 95% CI -2.283 to -0.898) but heterogeneity of 86.4%, with aerobic training showing the most consistent results and programs longer than 5 months doing better[10]. Its authors called the certainty low[10].
How much exercise the dose models suggest
Two 2026 analyses modeled weekly volume in MET-minutes (exercise intensity multiplied by time). One found a significant overall response starting at 730 MET-minutes a week, with HIIT reaching significance at 400 and both aerobic and combined training at 1,100[1]. The authors translated 1,100 into about 315 minutes of walking at 3.5 METs or 275 minutes of cycling at 4 METs[1]. Resistance training showed no statistically significant dose relationship[1].
The other placed the best overall response at 1,100 MET-minutes a week, with significance from 430 to 1,420[2]. Its estimates by exercise type differ from the first analysis: a minimum effective dose of 580 for aerobic training, and best doses of 570 for combined training and 550 for HIIT[2]. So the 315-minute walking figure is one model’s estimate, not a settled threshold. This analysis describes the overall curve as U-shaped, but the modeled estimate at 1,420 (SMD -0.56) was close to the one at 1,100 (SMD -0.62), and what changed above that was mainly the width of the uncertainty range[2]. That pattern may reflect thinner data at high volumes, and it should not be read as proof that more exercise backfires. These models also pool across studies, so they are not prescriptions tested in a trial.
A separate dose analysis of 40 trials and 2,190 people used energy deficit instead. Exercise lowered visceral fat by an effect size of -0.15 for each 1,000 calories of weekly deficit (95% CI -0.23 to -0.07)[6]. That suggests the energy expended matters, whichever format produces it.
Combined training and the scale of the change
A 2026 meta-analysis of 18 combined-training studies found visceral fat down (SMD -0.36, 95% CI -0.59 to -0.13) and a percentage drop about twice that of subcutaneous fat (ratio 1.96 ± 1.18)[9]. Its exploratory analysis favored at least 3 sessions a week, 60 minutes or more per session and more than 15 weeks, using vigorous aerobic work with moderate-to-low-intensity resistance[9].
For a sense of real-world size, a review of 12 trials and 591 adults with overweight or obesity reported percentages: visceral fat area down 7.1% and subcutaneous fat area down 9.1% compared with non-exercising controls[11]. Its regression suggested visceral fat responds more as intensity rises[11]. In the 18-month CENTRAL trial, added moderate activity (80% aerobic) produced more visceral loss on either diet, independent of weight loss (mean difference -6.67 cm², 95% CI -14.8 to -0.45)[12].
Exercise also has competition. In one review, calorie restriction reduced visceral fat with an effect size of -0.53 (95% CI -0.71 to -0.35), numerically larger than exercise at -0.28 (95% CI -0.37 to -0.19), with each compared against controls and most studies at moderate risk of bias[6]. Those figures are from different sets of trials, so they don’t show that dieting beats exercise in a direct test.
What the last-place rank for resistance training means
It ranks lowest for this one outcome, which does not make it useless. Effects against control were still significant in the larger of the two 2026 overweight and obesity analyses (SMD -0.41, 95% CI -0.63 to -0.20)[1], but not in the diabetes[4] or early cardiometabolic[5] networks. A subgroup analysis found visceral benefit in men and in people with body fat below 40%, but not in women or in those at 40% or above[3].
Lifting has a different job for many people on medication: holding on to lean mass during rapid weight loss, which is the case made in our guide to the best exercise on a GLP-1. None of the abstracts reviewed here reports results for people taking a GLP-1, so these rankings are borrowed from people not selected for that treatment. And no ranking here supports targeting the belly itself. Our menopause belly fat review covers a randomized trial of ab exercises that did not reduce abdominal fat.
What to raise with a clinician
- Whether high-intensity work is appropriate given your heart health, joints and current fitness, since the top-ranked option in several analyses is also the most demanding.
- If you take a GLP-1, how to time harder sessions around dose increases and stomach symptoms.
- If you have prediabetes or type 2 diabetes, whether a combined aerobic and strength plan suits you, since that combination ranked first in this group[4], and how exercise could affect your glucose-lowering medication.
- Which option you can sustain. Longer programs tended to do better in two of these reviews[5][10].
Our reviews
Strength-training apps we’ve reviewed
Workout apps and coaching for the exercise side of your plan. Each opens our full, independent review.
We may earn a commission from featured partners. Learn more
See the full ranking →Frequently Asked Questions
References
- 1.Chang Y, Wang L, Wang H, Zhan E. Unveiling the perfect workout: exercise modalities and dosages to combat visceral adipose tissue in individuals with overweight and obesity - a systematic review with pairwise, network, and dose-response meta-analyses. Nutr Metab (Lond). 2026. PMID: 42098808.
- 2.Xu W, Xie X, Liu H. Optimal exercise modality and dose for reducing visceral adipose tissue in overweight or obese adults: a network meta-analysis and dose-response study. BMC Sports Sci Med Rehabil. 2026. PMID: 42260656.
- 3.Chen X, He H, Xie K, Zhang L, Cao C. Effects of various exercise types on visceral adipose tissue in individuals with overweight and obesity: A systematic review and network meta-analysis of 84 randomized controlled trials. Obes Rev. 2024. PMID: 38031812.
- 4.Khalafi M, Fatolahi S, Symonds ME, Dinizadeh F, Rosenkranz SK, Batrakoulis A. Comparative Efficacy of Exercise Type on Visceral Adipose Tissue in Patients With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review With Pairwise and Network Meta-Analyses. Obes Rev. 2026. PMID: 41062106.
- 5.Wei X, Zhao H, Yue S, et al. Effects of different exercise types on visceral adipose tissue and glycemic parameters in adults with stage 1 cardiovascular-kidney-metabolic syndrome: a systematic review and network meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2026. PMID: 42872087.
- 6.Recchia F, Leung CK, Yu AP, et al. Dose-response effects of exercise and caloric restriction on visceral adiposity in overweight and obese adults: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med. 2023. PMID: 36669870.
- 7.Kramer AM, Martins JB, de Oliveira PC, Lehnen AM, Waclawovsky G. High-intensity interval training is not superior to continuous aerobic training in reducing body fat: A systematic review and meta-analysis of randomized clinical trials. J Exerc Sci Fit. 2023. PMID: 37927356.
- 8.Zhu X, Jiao J, Liang W, Wang X, Zhang H. Effect of low-volume interval training on whole-body, abdominal and visceral fat in adults living with overweight and obesity: A systematic review and meta-analysis. J Sports Sci. 2025. PMID: 40999737.
- 9.Lin X, Li G, Xie J, Wang S. Effects of concurrent training on fat mass and its distribution in individuals with overweight or obesity: a systematic review, meta-analysis, and exploratory regression analysis. BMC Public Health. 2026. PMID: 41862856.
- 10.Arazi H, Bagherpour F, Tinsley GM. Impact of Different Exercise Modalities on Visceral Adipose Tissue in Normal Weight and Low-Overweight Individuals: A Systematic Review and Meta-Analysis. Biol Res Nurs. 2026. PMID: 42284156.
- 11.Igarashi Y, Akazawa N, Maeda S. An exercise program to reduce abdominal visceral and subcutaneous fat in adults with overweight and obesity: A systematic review and meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2025. PMID: 41109785.
- 12.Gepner Y, Shelef I, Schwarzfuchs D, et al. Effect of Distinct Lifestyle Interventions on Mobilization of Fat Storage Pools: CENTRAL Magnetic Resonance Imaging Randomized Controlled Trial. Circulation. 2018. PMID: 29142011.
Related research
HIIT for Weight Loss: What the Evidence Actually Shows
What meta-analyses actually show for HIIT vs. moderate cardio, the real EPOC "afterburn" number, and how to pace HIIT intervals during GLP-1 dose titration.
9 min read
Time-Restricted Eating With Lifting: Fat Loss or Muscle Loss?
Short trials suggest time-restricted eating alongside resistance training may trim a little fat without clear muscle loss. Here is what new meta-analyses show, why calories and protein may explain much of it, and where the evidence stops.
8 min read
Low-Carb vs Low-Fat: Which Reduces Visceral Fat More?
Randomized trials that imaged or estimated visceral fat give low-carb a small edge in DIETFITS, but long-term pooled data show little difference. What the depot data, genotype analyses and lipid trade-offs mean.
7 min read
Best Exercise on a GLP-1: Strength + Cardio Plan
You don't have to exercise on a GLP-1, but resistance training protects muscle. An evidence-based weekly strength + cardio + steps plan.
9 min read
Sarcopenic Obesity and GLP-1 Drugs: Protecting Muscle While Losing Fat
Sarcopenic obesity — excess fat plus low muscle, at any age per the 2022 ESPEN/EASO consensus — collides with GLP-1 weight loss, where about a quarter to a third of weight lost can be lean mass. The evidence and the muscle-protective fix.
9 min read
Exercise on a GLP-1: Pilates, Walking, HIIT, and Resistance Training for Lean Mass Preservation
Resistance training paired with enough protein is the highest-leverage exercise on a GLP-1 for protecting lean mass. In S-LiTE, liraglutide plus exercise lost 9.5 kg more than placebo versus 6.8 kg for liraglutide alone. Pilates, yoga, walking, and HIIT are compared.
14 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →From $200/mo
starting dose
From $99/mo
From $139/mo
4-month plan rate